Ikena Oncology, Inc. (IKNA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Ikena Oncology reported revenue of $800,000. Net income was -$45.3M (a -5668.6% net margin), or -$9.64 per diluted share. Operating margin was -6056.4%. Operating activities generated -$47.8M of cash, leaving -$47.8M of free cash flow. At fiscal year end, Ikena Oncology held $153.0M in total assets against $19.8M in total liabilities, including $94.5M of cash and equivalents.
Open the full interactive Ikena Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Ikena Oncology Key Stats
| Share Price | $4.24 |
|---|---|
| Market Cap | $68.5M |
| 52-Week Range | $4.24 – $8.79 |
| Shares Outstanding | 11.3 million (basic, 2026 Q2) |
Ikena Oncology Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $31.0M | $15.6M | $9.2M | $0 | $800,000 |
| Operating Income | -$34.1M | -$70.9M | -$75.4M | -$59.0M | -$48.5M |
| Pre-Tax Income | -$34.1M | -$68.8M | -$68.3M | -$49.1M | -$45.7M |
| Income Tax | $0 | $0 | -$162,000 | $152,000 | -$350,000 |
| Net Income | -$34.1M | -$68.8M | -$68.2M | -$49.2M | -$45.3M |
| Diluted EPS | -$14.64 | -$22.80 | -$19.56 | -$12.24 | -$9.64 |
Ikena Oncology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $800,000 | $0 | $0 |
| Net Income | -$24.8M | -$9.2M | -$10.6M | -$10.2M |
| Diluted EPS | -$2.91 | — | -$0.95 | -$0.63 |
Ikena Oncology Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $232.2M | $59.9M | $119.9M | $39.4M | $94.5M |
| Current Assets | $236.5M | $160.0M | $178.7M | $127.2M | $140.3M |
| Total Assets | $247.9M | $172.3M | $192.1M | $141.5M | $153.0M |
| Current Liabilities | $27.2M | $21.5M | $14.2M | $10.8M | $11.2M |
| Total Long-Term Debt | — | — | $950,000 | $1.1M | — |
| Total Liabilities | $40.0M | $25.3M | $22.3M | $15.6M | $19.8M |
| Shareholders' Equity | $207.9M | $147.0M | $169.8M | $125.9M | $133.1M |
Ikena Oncology Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$60.3M | -$74.1M | -$79.7M | -$46.0M | -$47.8M |
| Cash From Investing | -$1.8M | -$99.3M | $64.1M | -$34.9M | -$5.8M |
| Cash From Financing | $131.7M | $1.1M | $76.0M | — | $135.5M |
| Free Cash Flow | -$62.0M | -$75.5M | -$80.2M | -$46.4M | -$47.8M |
Figures from Ikena Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ikena Oncology financials page for every line item.
Ikena Oncology Company Profile
| Ticker | IKNA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001835579 |
Frequently Asked Questions
What was Ikena Oncology's revenue in fiscal 2025?
Ikena Oncology (IKNA) reported revenue of $800,000 for fiscal 2025.
What is Ikena Oncology's annual revenue history?
Ikena Oncology's annual revenue by fiscal year: 2021: $31.0M; 2022: $15.6M; 2023: $9.2M; 2024: $0; 2025: $800,000.
What was Ikena Oncology's net income in fiscal 2025?
Ikena Oncology reported net income of -$45.3M for fiscal 2025.
What was Ikena Oncology's earnings per share (EPS) in fiscal 2025?
Ikena Oncology's diluted EPS was -$9.64 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ikena Oncology generate in fiscal 2025?
Ikena Oncology generated -$47.8M of free cash flow in fiscal 2025.
What was Ikena Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Ikena Oncology reported revenue of $0.
How many shares of Ikena Oncology are outstanding?
Ikena Oncology reported a weighted average of 11.3 million basic shares outstanding in 2026 Q2.
What is Ikena Oncology's market cap?
Based on its latest closing price, Ikena Oncology (IKNA) has a market capitalization of about $68.5M.
When does Ikena Oncology's fiscal year end?
Ikena Oncology's fiscal year end, as registered with the SEC, is December 31.
Where is Ikena Oncology headquartered?
Ikena Oncology lists its business address in San Diego, California in its SEC filings.
Ikena Oncology Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →